Sign In
Buy CPRX
$31.49
+0 (+0%)
At Close: Jul 31, 2026
Earnings Preview: Catalyst Pharmaceutical (CPRX) Q3 Earnings Expected to Decline
11:01am, Wednesday, 29'th Oct 2025
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DekaBank Deutsche Girozentrale Purchases 12,000 Shares of Catalyst Pharmaceuticals, Inc. $CPRX
04:12am, Sunday, 26'th Oct 2025
DekaBank Deutsche Girozentrale boosted its position in Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) by 7.0% in the second quarter, according to the company in its most recent disclosure with the Secu
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
10:46am, Friday, 24'th Oct 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025
08:03am, Wednesday, 22'nd Oct 2025
The Company will Host a Conference Call and Webcast on Thursday, November 6, 2025, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, November 6, 2025, at 8:30 AM ET
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
10:50am, Friday, 10'th Oct 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
08:03am, Thursday, 09'th Oct 2025
CORAL GABLES, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and c
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term
10:46am, Wednesday, 08'th Oct 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program
08:03am, Wednesday, 01'st Oct 2025
CORAL GABLES, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licens
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term
10:46am, Monday, 22'nd Sep 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Catalyst Pharmaceutical (CPRX) is a Top-Ranked Value Stock: Should You Buy?
10:41am, Monday, 15'th Sep 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock
10:41am, Friday, 29'th Aug 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
08:03am, Thursday, 28'th Aug 2025
CORAL GABLES, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
07:12pm, Tuesday, 26'th Aug 2025
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in Fe
Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin
12:21pm, Tuesday, 26'th Aug 2025
CPRX secures a key win as its Firdapse patent litigation settlement with Lupin shields U.S. sales from generic competition until 2035.
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
08:03am, Monday, 25'th Aug 2025
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in Fe
